Fact CheckerSign in

NCT07724171Recruiting

Long-term Outcomes After Percutaneous Patent Foramen Ovale Closure (Severance PFO Registry)

Long-term Clinical Outcomes and Prognostic Factors After Percutaneous Patent Foramen Ovale Closure: A Retrospective Cohort Study With Prospective Registry Extension

Source: ClinicalTrials.gov · Last updated 23 Jul 2026

Brief summary (registry, in English)

Patent foramen ovale (PFO) is a congenital interatrial communication present in about one quarter of the general population and is recognized as a major cause of cryptogenic stroke. Percutaneous PFO closure reduces recurrent stroke, but a residual right-to-left shunt persists in 20 to 40 percent of patients after device implantation. Long-term data on device performance, the evolution of residual shunt over time, new-onset atrial fibrillation and other prognostic factors remain limited. This single-center registry evaluates the long-term efficacy and safety of percutaneous PFO closure and identifies the clinical, anatomical, procedural and pharmacological factors associated with clinical and echocardiographic outcomes. The registry combines a retrospective cohort of patients treated at Severance Hospital between 2010 and March 2026 with a prospective registry extension that enrolls patients undergoing PFO closure after institutional review board approval, with follow-up for up to 119 months. Clinical outcomes include recurrent ischemic stroke or transient ischemic attack, all-cause death, device-related complications and new-onset atrial fibrillation. Echocardiographic outcomes are assessed by serial agitated saline transthoracic echocardiography, which allows the presence, grade and longitudinal trajectory of residual shunt to be characterized.

Status (registry)
Recruiting
Study type
Observational
Enrollment
400 (estimated)
First submitted
13 Jul 2026
Start date
5 Jun 2026
Primary completion date
4 May 2036
Lead sponsor
Yonsei University
NCT number
NCT07724171

What you commit to

  • Study type: Observational
  • Planned participants: 400
  • From 5 Jun 2026 to the primary completion date, 4 May 2036
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Atrial septal defect closure (defect other than patent foramen ovale)
  • Device embolization or device removal
  • Echocardiographic image quality inadequate for assessment of shunt
  • Prospective cohort: refusal of informed consent

Who the study is looking for

  • Age 19 years or older
  • Percutaneous patent foramen ovale closure
  • Retrospective cohort: closure performed between 2010 and March 2026, with at least one post-procedural agitated saline transthoracic echocardiography
  • Prospective cohort: closure performed after institutional review board approval, with written informed consent

Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Yonsei University College of Medicine
Coordinator of this site? Confirm its status
SeoulSouth KoreaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.